Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit
Rhea-AI Summary
Serina Therapeutics (NYSE American: SER) will present at the 5th LNP Formulation & Process Development Summit on April 7, 2026 in Boston.
Presentation titled "Novel Lipid Nanoparticles Built Entirely on a POZ Platform" will show that Serina’s POZ-lipid failed to elicit an antibody response in a vaccine-format rat study and previews a polymer‑lipid designed to bind diverse oligonucleotide payloads. Serina is also advancing POZ replacements for ionizable lipids to address LNP safety and versatility concerns.
Positive
- None.
Negative
- None.
News Market Reaction – SER
On the day this news was published, SER declined 3.26%, reflecting a moderate negative market reaction. Argus tracked a trough of -6.3% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $892K from the company's valuation, bringing the market cap to $26.48M at that time.
Data tracked by StockTitan Argus on the day of publication.
Market Reality Check
Peers on Argus
SER gained 1.42% while peers were mixed: VTVT up 2.86%, JUNS down 7.51%, PYPD down 3.85%, RLMD up 0.29%, MAIA down 0.77%. Momentum scanner shows both up and down moves, indicating stock-specific factors rather than a unified biotech move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 25 | Full-year results | Positive | -13.9% | Year-end 2025 results plus IND clearance and financing updates. |
| Mar 24 | Conference appearance | Neutral | -22.9% | CEO fireside chat at a major investor conference. |
| Mar 18 | Private placement | Positive | +93.8% | Up to $30M private placement and warrant proceeds to fund SER-252 trial. |
| Feb 24 | Trial dosing update | Positive | +6.0% | First patient dosed in Phase 1b registrational SER-252 study. |
| Feb 19 | Trial enrollment | Positive | +3.0% | First patient enrolled in Phase 1b SER-252 trial for Parkinson’s. |
Recent history shows strong positive reaction to financing, but selling pressure after earnings and some neutral news.
Over the past few months, Serina reported multiple milestones. A Feb 19 announcement of first patient enrollment and a Feb 24 dosing update for the SER-252 Phase 1b trial both saw modest positive reactions. A Mar 18 private placement of up to $30 million with warrant coverage drew a strong 93.75% move. By contrast, full-year 2025 results on Mar 25 and a Mar 24 conference appearance were followed by double‑digit declines. Against this backdrop, today’s LNP platform presentation fits the pattern of ongoing platform and pipeline visibility efforts.
Regulatory & Risk Context
An effective S-3 shelf dated 2026-01-30 registers 7,722,006 common shares for resale tied to a 2025 senior unsecured convertible note and related warrants. The company will not receive proceeds from these resales, although the underlying note provides funding up to $20 million at 10% interest with specified conversion and warrant exercise prices.
Market Pulse Summary
This announcement highlights preclinical data that Serina’s POZ-based lipid nanoparticles avoided antibody responses seen with PEG-lipids, and introduces an ionizable lipid replacement strategy for broad oligonucleotide delivery. It complements prior updates on SER-252 and financing. Investors may watch for further in vivo data, partnering activity leveraging the POZ LNP platform, and any future use of the registered 7,722,006 resale shares tied to the company’s convertible note structure.
Key Terms
lipid nanoparticles medical
peg immunogenicity medical
ionizable lipids medical
oligonucleotide payloads medical
igm medical
igg medical
AI-generated analysis. Not financial advice.
– Novel lipid nanoparticles entirely built on the POZ Platform that overcome the PEG immunogenicity dilemma
– Design & synthesis of novel ionizable POZ lipids to replace current ionizable lipids for the delivery of a multitude of oligonucleotide payloads –
HUNTSVILLE, AL, April 07, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Serina Therapeutics Chief Development Officer, Randall Moreadith, MD, PhD, will be presenting today at the 5th LNP Formulation & Process Development Summit in Boston, MA.
Entitled "Novel Lipid Nanoparticles Built Entirely on a POZ Platform", Dr. Moreadith will present data demonstrating the POZ-lipid in Serina’s platform failed to elicit an antibody response to the polymer in a vaccine format in the rat. The standard PEG-lipid in most LNP formulations elicits a prompt IgM and IgG response and has been shown to be associated with serious adverse events in some individuals. The Serina LNP Laboratory is also advancing an additional replacement strategy targeting ionizable lipids, another essential LNP component that has been implicated in safety concerns. Preliminary results from Serina’s studies of a novel polymer‑lipid designed to bind a broad range of oligonucleotide payloads will also be featured in the presentation, underscoring the company’s commitment to improving both the safety and versatility of LNP‑based therapeutics.
About Serina Therapeutics
Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina's POZ Platform™ provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology.
About the POZ Platform™
Serina's proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly (2-oxazoline). Serina's POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. The therapeutic agents in Serina's product candidates are typically well-understood and marketed drugs that are effective but are limited by pharmacokinetic profiles that can include toxicity, side effects and short half-life. Serina believes that by using POZ technology, drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the blood.
Serina's POZ platform delivery technology has potential for use across a broad range of payloads and indications. Serina intends to advance additional applications of the POZ platform via out-licensing, co-development, or other partnership arrangements, including the non-exclusive license agreement with Pfizer, Inc. to use Serina's POZ polymer technology for use in lipid nanoparticle drug (LNP) delivery formulations.
For more information, please visit https://serinatx.com.
Cautionary Statement Regarding Forward-Looking Statements
This release contains forward-looking statements within the meaning of federal securities laws. All statements that are not historical fact, including statements about Serina's planned clinical programs, including timing for patient enrollment and dosing, the potential of Serina's POZ polymer technology, and the Company's ability to advance its clinical trial, are forward-looking statements that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements are based on management's current expectations, plans, beliefs or forecasts for the future, and are subject to uncertainty and changes in circumstances. Undue reliance should not be placed on these forward-looking statements which speak only as of the date they are made, and the facts and assumptions underlying these statements may change.
Actual results may differ materially from those projected in such statements due to a variety of important factors including, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; Serina's ability to continue as a going concern; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any applications may be filed for any drug or vaccine candidates in any jurisdictions; whether and when regulatory authorities may approve any potential applications that may be filed for any drug or vaccine candidates in any jurisdictions, which will depend on a myriad of factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether any such drug or vaccine candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of any drug or vaccine candidates; and competitive developments. These risks as well as other risks are more fully discussed in the company's Annual Report on Form 10-K for the year ended December 31, 2025, and the company's other periodic reports and documents filed from time to time with the SEC. The information contained in this release is as of the date hereof, and Serina assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
For inquiries, please contact:
Stefan Riley
sriley@serinatherapeutics.com
(256) 327-9630
